Can-Fite BioPharma submits Piclidenoson pediatric study plan to FDA

Can-Fite BioPharma announced that it submitted a pediatric study plan to the FDA for the treatment of adolescents suffering from psoriasis with Piclidenoson. The plan has been submitted to allow enrollment of adolescents with psoriasis to Can-Fite’s upcoming two Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA and the European Medicines Agency for the treatment of plaque psoriasis.